The hypothesis that a therapeutic strategy aimed at lowering systolic blood pressure (SBP) below 130 mm Hg is superior to a conventional strategy targeted at below 140 mm Hg in hypertensive subjects has never been tested in randomized intervention studies. The Studio Italiano Sugli Effetti Cardiovascolari del Controllo della Pressione Arteriosa Sistolica (Cardio-Sis) is a multicentre study in non-diabetic, treated hypertensive subjects aged 455 years with uncontrolled SBP (X150 mm Hg) and at least one additional cardiovascular risk factor (ClinicalTrials.gov identifier: NCT00421863). Subjects are randomized to an SBP goal o140 mm Hg (conventional) or o130 mm Hg (aggressive), independently of baseline and achieved diastolic blood pressure (BP). Anti-hypertensive drugs dispensed for the study are restricted to a list of specific drugs. The primary outcome of the study is based on regression of left ventricular hypertrophy (LVH) using electrocardiography (ECG). The hypothesis is that subjects without LVH regression or with new development of LVH 2 years after randomization are 19% with conventional strategy and 12% with aggressive strategy. Secondary outcome is a composite pool of pre-specified fatal and non-fatal events. Randomization of 1111 subjects was completed by February 2007. Mean age of subjects (41% men) at entry was 67 years. BP was 158/ 87 mm Hg (systolic/diastolic) and prevalence of LVH by ECG was 21.0%. Cardio-Sis is the first randomized study specifically designed to compare two different SBP goals. Results will be broadly applicable to subjects with uncontrolled SBP under anti-hypertensive treatment.
Introduction
Only a minority of treated hypertensive subjects achieve adequate blood pressure (BP) control as suggested by guidelines, [1] [2] [3] [4] although it is well established that poor BP control identifies subjects at increased cardiovascular risk. [5] [6] [7] The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure suggests that the goal of anti-hypertensive treatment should be the reduction of BP to o140/90 mm Hg, and to o130/80 mm Hg in patients with diabetes and chronic renal disease. 1 The 2007 European Society of Hypertension/European Society of Cardiology Guidelines suggest that BP goal should be o140/90 mm Hg in all hypertensive patients, and o130/80 mm Hg in diabetics and high or very high risk patients. 2 However, despite the epidemiological evidence of a continuous relation between BP and cardiovascular risk starting from 115/75 mm Hg 8 and retrospective analyses of available trials, [9] [10] [11] [12] there are no randomized prospective intervention studies showing that a systolic blood pressure (SBP) goal o130 mm Hg is superior to a conventional goal (o140 mm Hg) in terms of cardiovascular protection in high-risk hypertensive subjects. Table 1 shows the available randomized trials that compared different BP goals. None of these studies compared different SBP targets in non-diabetic hypertensive subjects.
Consequently, The Studio Italiano Sugli Effetti Cardiovascolari del Controllo della Pressione Arteriosa Sistolica (Italian Study on Cardiovascular Effects of Systolic Blood Pressure Control, Cardio-Sis) was planned to test the hypothesis that a therapeutic strategy based solely on reduction of SBP o130 mm Hg is superior to a traditional strategy based on SBP reduction o140 mm Hg in non-diabetic hypertensive subjects. The primary end point is based on the hypothesis that the different strategies are associated with different changes in left ventricular hypertrophy (LVH) by electrocardiography (ECG), used as an intermediate outcome measure.
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Materials and methods
Cardio-Sis is a prospective multi-centre, randomized study with two parallel groups.
Study objectives
The primary objective of the study was the comparison between two SBP goals (o130 mm Hg, labelled as 'aggressive' and o140 mm Hg labelled as 'conventional') on the 2-year modification of ECG-LVH evaluated by the Perugia score, 17, 18 which is defined by the presence of at least one of the following three criteria: The secondary objective of the study was the comparison between two SBP goals in the incidence of a composite pool of pre-specified fatal and nonfatal events (fatal and non-fatal myocardial infarction, fatal and non-fatal strokes, transient ischaemic attack, sudden cardiac death, death due to other cardiovascular causes, death due to non-cardiovascular causes, congestive heart failure, New York Heart Association (NYHA) stage III or IV requiring hospitalization, angina with objective evidence of myocardial ischaemia, new onset atrial fibrillation, coronary re-vascularization (bypass or angioplasty, peripheral occlusive arterial disease, renal failure requiring dialysis, aortic dissection). For patients with more than one event, the survival time up to the first event was used in the analysis. The comparison between the two groups in the serial changes in systolic and diastolic BP was another secondary end point of the study.
Patients
Eligible patients were men or women aged 455 years at randomization and with uncontrolled SBP (that is, X150 mm Hg) during prolonged (that is, X12-week duration) anti-hypertensive treatment. Inclusion criteria are detailed in Table 2 . Exclusion criteria were diabetes, defined by fasting glucose 4125 mg dl À1 in two samples or ongoing antidiabetic treatment. Renal failure, defined by a serum creatinine 42.0 mg dl À1 , chronic atrial fibrillation or flutter, clinically significant hepatic or haematological disorders, alcoholism, drug addiction, causes Overview of study procedures The study procedures are summarized in the Figure 1 . During an initial run-in period, two qualifying visits 7-14 days apart were carried out to establish whether BP remains uncontrolled (SBPX150 mm Hg) under current treatment. At the end of the second visit, eligible patients were randomized to one of the two BP goals outlined above. Routine laboratory tests (total, high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol, triglycerides, uric acid, aspartate aminotransferase, alanine aminotransferase, sodium, potassium, glucose, creatinine, uric acid and urinalysis) and a 12-lead ECG were carried out in this visit. Subsequent clinical visits were scheduled at 4-month intervals up to the end of the study (24 months after randomization). A complete clinical examination was carried out at each visit. ECG and routine laboratory tests were carried out at randomization and after 12 and 24 months.
Blood pressure measurement BP was measured by a physician through a standard mercury sphygmomanometer. Subjects were maintained in sitting position and relaxed for at least 10 min before measurements. SBP was taken at Korotkoff phase I and diastolic BP at phase V. Three office BP measurements 2-3 min apart were recorded.
Anti-hypertensive drugs
Anti-hypertensive therapy was open-label and tailored to the single subjects. Because achievement of optimal SBP control is expected to require additional drugs on top of those previously taken Control of systolic blood pressure Cardio-Sis Study Group by subjects, treatment included different combinations of prior drugs (background therapy) plus drugs dispensed for the present study. The list of antihypertensive drugs dispensed for the purpose of the study was restricted according to the list outlined in Table 3 .
Adjustment of treatment
In the aggressive strategy group, even one single SBP measurement 4130 mm Hg is enough to intensify treatment. In the conventional strategy group, achievement of SBP goal o130 mm Hg does not imply downtitration of treatment.
Sample size and data analysis Sample size was calculated according to the following estimates:
(1) ECG LVH at randomization in 25% of subjects. The hypothesis that a 24% reduction in the frequency of LVH (that is from 25 to 19%) in the conventional strategy group is derived from previous observational data indicating a 27% reduction in the frequency of ECG LVH (estimated through the Perugia score 17, 18 ) during standard treatment. 19 We hypothesized a further absolute 7% reduction in association with a targeted SBP drop by further 10 mm Hg. According to the above points, 484 subjects per group (968 total) were needed to demonstrate the primary hypothesis. With a 2-year dropout rate set at 12%, 1100 patients were required for randomization.
Statistical analysis was based on the intention-totreat principle. The primary objective of the study was evaluated by using the w 2 distribution. For assessment of the secondary objective of the study, analysis was restricted to the first event in subjects with multiple events. Survival curves were estimated using Kaplan-Meier product-limit method and compared by the Mantel (log-rank) test. The effect of prognostic factors on survival was evaluated by stepwise Cox semi-parametric regression model. 20 Organizational structure Cardio-Sis is registered at the National Institute of Health (ClinicalTrials.gov identifier: NCT00421863). The sponsor of the study was the Heart Care Foundation (Fondazione Italiana per la Lotta alle Malattie Cardiovascolari), a non-profit independent institution, which is also the owner of the database. An international steering committee was responsible for the scientific integrity, conduct and publication policy of the study. An independent end point adjudication committee, unaware of randomization code, was responsible to review and adjudicate incident clinical events (secondary objective) on the basis of original documentation provided by local investigators (see Appendix for events definitions).
Cardio-Sis has its central administration and monitoring office at the research centre of the Italian Association of Hospital Cardiologists (ANMCO) in Florence, Italy. ECG tracings were coded and shipped to a central reading laboratory. ECG reading was carried out by expert readers unaware of randomization code and clinical characteristics of patients. The Cardio-Sis clinical record form (CRF) was developed by the ANMCO Research Centre and Clinical Research Technology S.r.l., Salerno, Italy (www.cr-technology.com). It runs entirely on the Web (www.cardio-sis.it). Drug supply to centres was automatically updated on the basis of local needs as resulting from CRF.
Ethics
Before beginning of the study, each participating centre received written approval from the competent ethics committee and university/hospital authorities. Table 4 shows the main clinical characteristics of patients at randomization. Mean age was 67 years and mean systolic and diastolic BP was 158/87 mm Hg. Prevalence of LVH at ECG 17, 18 was 21%, that is 4% lower than expected. Increased Cornell voltage (42.0 mV in women and 42.4 mV in men) was present in 15.7% of subjects, typical strain pattern in 6.4% and a Romhilt-Estes point scoreX5 in 4.1% subjects. The three components of the Perugia score were variously combined in some of the subjects.
Results
Baseline clinical characteristics of patients
Concomitant risk factors
Overall, 20.4% of subjects were current smokers. The average waist girth was 98.4 cm (488 cm in 74% of women and 4102 cm in 45% of men). An impaired fasting glucose (4110 mg dl À1 ) was present in 40.1% of subjects. Overall, 75.9% of subjects had total cholesterolX200 mg dl À1 or HDL cholesterol o40 mg dl À1 or LDL cholesterol X130 mg dl À1 , 27.5% family history of premature cardiovascular disease, 8.1% prior evidence of stroke or TIA, 11.5% prior evidence of coronary artery disease and 2.7% had prior evidence of occlusive peripheral arterial disease. Overall, 62, 31, 6 and 1% of subjects had 1, 2, 3 or X4 concomitant risk factors, respectively. Metabolic syndrome by ATPIII criteria was present in 39.9% of subjects. When counting baseline ECG LVH as an additional risk factor, the prevalence of subjects with 1, 2, 3 or X4 concomitant risk factors was 49, 39, 10 and 2%, respectively.
Discussion
Cardio-Sis is the first randomized study specifically designed to compare the effects of two different SBP goals (o130 and o140 mm Hg). The decision to base BP goals solely on SBP is supported by the strong evidence that, over age 55, SBP is the major determinant of cardiovascular risk 21, 22 and the main target of anti-hypertensive treatment. 23 
Outcome measures
Cost reasons precluded the design of a study primarily targeted on major cardiovascular events. The decision of adopting ECG LVH as intermediate outcome measure was supported by evidence that ECG LVH is a potent and independent predictor of adverse outcome, 13 also when assessed in terms of serial changes during treatment [14] [15] [16] or before an incident event. 24 Indeed, consensus has been reported among experts that LVH regression may be considered as a surrogate outcome measure. 25 In the Framingham Heart Study, 14 subjects with baseline LVH and serial increase over time in the ECG voltages were twice as likely to suffer a cardiovascular event over the subsequent years than subjects with a decrease in the voltages. In a post hoc analysis of the Heart Outcome Prevention Evaluation study, 15 the primary study outcome occurred in 12.3% of subjects with absence of LVH or its regression during the study, and in 15.8% of subjects with development or lack of regression of LVH during the study (P ¼ 0.006).
Among the available ECG indexes of LVH, the Perugia score showed the highest sensitivity 17 and population attributable risk. 18 In the Losartan Intervention For Endpoint study, the diagnostic performance of the Perugia score was superior to that of the Sokolow-Lyon index, and was comparable to that of the Cornell voltage-duration product, in overweight and obese individuals. 26 In the HEART Survey study, carried out in 711 hypertensive subjects with LVH at entry defined by the Perugia score, regression of ECG LVH at follow-up conferred a 54% lesser risk of primary outcome events (95% confidence interval 16-75). 16 The secondary outcome measures in Cardio-Sis were all-cause mortality and a composite pool of pre-specified fatal and non-fatal events. Although the study is not powered to test the hypothesis of a different incidence of major events in relation to the achieved BP gradient between the two groups, some data suggest that an early aggressive control of BP may result in a consistent protection from cardiovascular events even in a relatively short term. 27 Blood pressure goals None of the available intervention studies was specifically designed to compare two different SBP targets in non-diabetic hypertensive individuals. In the Hypertension Optimal Treatment study, a significant reduction in the incidence of major cardiovascular events in the target group p80 mm Hg as compared to the target group p90 mm Hg (51% reduction, P ¼ 0.005) was found only in the diabetic subset. 9 In the Afro-American study of kidney disease and hypertension, 10 1094 African-Americans aged 18-70 years with hypertension and nephropathy were randomly assigned to a less aggressive (102-107 mm Hg) or more aggressive (p92 mm Hg) target based on mean BP. Although achieved BP averaged 128/78 mm Hg in the more aggressive arm and 141/85 mm Hg in the less aggressive arm, neither the progression of renal function nor the incidence of a composite pool of cardiovascular events differed between the groups. 10 The Appropriate Blood Pressure Control in Diabetes Trial compared a diastolic BP goal 80-89 mm Hg with a more aggressive goal (75 mm Hg) in a sample of 470 subjects with type 2 diabetes and baseline diastolic BPX90 mm Hg. 11 The mean BP achieved during a 5.6-year follow-up period was 132/78 mm Hg in the more aggressive arm and 138/86 mm Hg in the less aggressive arm. Death rate was less frequent in the more aggressive than in the less aggressive arm (5.5 versus 10.7%, P ¼ 0.037), but no differences were found between the two arms in terms of progression of diabetic nephropathy, neuropathy and retinopathy. 11 In the United Kingdom Prospective Diabetes Study 38 12 of 1148 hypertensive patients with type 2 diabetes were randomized to a more tight (o150/ 85 mm Hg) or less tight (o180/105 mm Hg) BP target. During a follow-up period of 8.4 years, mean achieved BP was lower (Po0.0001) in the more aggressive (144/82 mm Hg) than in the less aggressive (154/87 mm Hg) strategy group. Despite the relatively high-achieved BP values, individuals randomized to the more aggressive strategy showed a significantly lesser incidence of diabetes related end points, deaths related to diabetes, stroke and microvascular end points. 12 Taken together, the available intervention studies either addressed BP targets based on diastolic or mean BP, or examined specific populations composed by diabetic patients or patients with hypertension and nephropathy. Although the most recent European Society of Hypertension/European Society of Cardiology guidelines presented a list of clinical conditions defining an increased cardiovascular risk in hypertensive subjects for reasons different from diabetes, 2 randomized trials comparing different SBP targets were not available in those conditions.
Limitations of the study
The main limitation of Cardio-Sis is that major cardiovascular events are a secondary, although pre-specified, end point of the study. Furthermore, lack of ambulatory BP measurements could lead to inclusion of a number of subjects with white-coat, or isolated clinic, hypertension. However, since SBP had to be 4150 mm Hg in two visits before randomization and subjects had to be treated in both visits, such a possibility was unlikely in most subjects. 28 What is known about the topic K Hypertension guidelines suggest that the goal of antihypertensive treatment should be the reduction of BP to o130/80 mm Hg in patients with diabetes or chronic renal disease, and to o140/90 mm Hg in the other patients. K Systolic blood pressure is the main determinant of cardiovascular risk and target of treatment after the age of 55. K There are no randomized intervention trials demonstrating that a systolic blood pressure goal o130 mm Hg is superior to a conventional goal (o140 mm Hg) in terms of cardiovascular protection in high-risk hypertensive subjects without diabetes.
What this study adds K Cardio-Sis is the first randomized study specifically designed to compare two different systolic blood pressure goals. K The primary end point is based on left ventricular hypertrophy regression, an established surrogate outcome measure. A composite pool of pre-specified events will be evaluated as a secondary end point. K Conclusions of Cardio-Sis will be useful in the management of hypertensive subjects with uncontrolled systolic blood pressure under treatment.
within 1 h from onset of symptoms, in the absence of any known relation with traumatic or violent causes. 'Death due to other cardiovascular causes' is defined by a cardiovascular death different from myocardial infarction or stroke (for example, death due to heart failure or aortic dissection).
'Congestive heart failure' NYHA stage III or IV is defined by congestive heart failure with dyspnoea induced by a lesser than usual physical activity (stage III) or at rest (stage IV) associated with hospitalization and treatment of the patient.
'Angina with objective evidence of myocardial ischaemia' is defined by new onset chest pain associated with objective evidence of myocardial ischaemia at ECG, radionuclide study or stress echocardiography, or with angiographic evidence of at least 50% stenosis in 4 ¼ 2 major epicardial vessels.
'Peripheral occlusive arterial disease' is defined by intermittent claudication associated with angiographic or ecographic evidence of arterial stenosis 460%.
